| Product NDC: | 0003-3624 |
| Proprietary Name: | REYATAZ |
| Non Proprietary Name: | ATAZANAVIR SULFATE |
| Active Ingredient(s): | 150 mg/1 & nbsp; ATAZANAVIR SULFATE |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE, GELATIN COATED |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0003-3624 |
| Labeler Name: | E.R. Squibb & Sons, L.L.C. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021567 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20030624 |
| Package NDC: | 0003-3624-12 |
| Package Description: | 60 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3624-12) |
| NDC Code | 0003-3624-12 |
| Proprietary Name | REYATAZ |
| Package Description | 60 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3624-12) |
| Product NDC | 0003-3624 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | ATAZANAVIR SULFATE |
| Dosage Form Name | CAPSULE, GELATIN COATED |
| Route Name | ORAL |
| Start Marketing Date | 20030624 |
| Marketing Category Name | NDA |
| Labeler Name | E.R. Squibb & Sons, L.L.C. |
| Substance Name | ATAZANAVIR SULFATE |
| Strength Number | 150 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC] |